Medicus 2014;23(2):117-126
125
LITERATURA
1.
MonteAA,HeardKJ, VasiliouV. Predictionof drug response and safety
inclinicalpractice.JMedToxicol2012;8:43–51.
2.
Spintge R, Loewy JV. At a Crossroads. Big Questions- Little Knowled-
ge in Achievements, With Issues of Translation. Music and Medicine
2011;3:209–12.
3.
CoenM,RueppSU,LindonJC isur. Integratedapplicationoftranscrip-
tomics and metabonomics yields new insight into the toxicity due to
paracetamolinthemouse.JPharmBiomedAnal.2004;35:93–105.
4.
Clayton TA, Lindon JC, Cloarec O i sur. Pharmaco-metabonomic phe-
notypingandpersonalizeddrugtreatment.Nature2006;440:1073–77.
5.
Neville KA, Becker ML, Goldman JL, Kearns GL. Developmental phar-
macogenomics.PaediatrAnaesth2011;21:255–65.
6.
Yang X, Zhang B, Molony C i sur. Systematic genetic and genomic
analysisofcytochromeP450enzymeactivitiesinhumanliver.Genome
Research2010;20:1020–36.
7.
Stamer UM, Zhang L, Stüber F. Personalized therapy in pain manage-
ment:wheredowestand?Pharmacogenomics2010;11:843–64.
8.
Samer CF, Dayer P, Desmeules JA. Howclose arewe to individual anal-
gesic adjustment according to a patient’s genotype? Personalized Med
2011;8:289–292.
9.
RollasonV, Samer C, Piguet V, Dayer P, Desmeules J. Pharmacogenetics
of analgesics: toward the individualization of prescription. Pharmaco-
genomics2008;9:905–33.
10. Stamer UM, LehnenK, Höthker F i sur. Impact of CYP2D6 genotype on
postoperativetramadolanalgesia.Pain2003;105:231–8.
11. Kirchheiner J, Keulen JT, Bauer S, Roots I, Brockmöller J. Effects of
the CYP2D6 gene duplication on the pharmacokinetics and pharma-
codynamicsoftramadol.JClinPsychopharmacol2008;28:78–83.
12. Samer CF, Desmeules JA, Dayer P. Individualizing analgesic prescrip-
tion. Part II: pharmacogenetics of anti-inflammatory analgesics and
co-analgesics.PersMed2006;3:271–97.
13. Jakobović J. Specifičnosti farmakokinetike i farmakodinamike analge-
tikaudjece.PaediatrCroat2011;55:35–41.
14. Brousseau DC, McCarver DG, Drendel AL, Divakaran K, Panepinto JA.
TheeffectofCYP2D6polymorphismsontheresponsetopaintreatment
forpediatricsicklecellpaincrisis.JPediatr2007;150;623–6.
15. Temesvári M, Kóbori L, Paulik J, Sárváry E, Belic A, Monostory K. Esti-
mationof drug-metabolizing capacityby cytochromeP450genotyping
andexpression.JPharmacolExpTher2012;341:294–305.
16. Robinette SL, Holmes E, Nicholson JK, Dumas ME. Genetic determi-
nants of metabolism in health and disease: from biochemical genetics
togenome-wideassociations.GenomeMed2012;4:30.
17. BictashM, Ebbels TM, ChanQ i sur. Openingup the „BlackBox“:meta-
bolic phenotyping andmetabolome-wide association studies in epide-
miology.JClinEpidemiol2010:63:970–9.
18. Baraldi E, Carraro S, Giordano G, Reniero F, Perilongo G, Zacchello F.
Metabolomics: moving towards personalized medicine. Ital J Pediatr
2009;35:30–4.
19. Roux A, Lison D, Junot C, Heilier JF. Applications of liquid chromato-
graphy coupled to mass spectrometry-based metabolomics in clinical
chemistryandtoxicology:Areview.ClinBiochem2011;44:119–35.
20. Wagner S, Scholz K, SieberM, KellertM, VoelkelW. Tools inmetabono-
mics: An integrated validation approach for LC-MSmetabolic profiling
ofmercapturicacidsinhumanurine.AnalChem2007;79:2918–26.
21. Patti GJ, Yanes O, Shriver LP i sur. Metabolomics implicates altered
sphingolipids in chronic pain of neuropathic origin. Nat Chem Biol
2012;8:232–4.
22. Legg K. Metabolomics: Gaining insight into pain. Nat Rev Drug Discov
2012;11:188–9.
23. LooRL, ChanQ, Brown IJ i sur. Acomparisonof self-reportedanalgesic
use and detection of urinary ibuprofen and acetaminophen metaboli-
tesbymeansofmetabonomics:theINTERMAPStudy.AmJEpidemiol
2012;175:348–58.
24. Lindon JC, Holmes E, Nicholson JK. Metabonomics techniques and
applications to pharmaceutical research & development. Pharmaceut
Res2006;23:1075–88.
25. Lindon JC, Nicholson JK, Holmes E i sur. Summary recommendations
forstandardizationandreportingofmetabolicanalyses.NatBiotechnol
2005;23:833–8.
26. Holmes E, Wilson ID, Nicholson JK. Metabolic phenotyping in health
anddisease.Cell2008;134:714–7.
27. WesthoffM, Litterst P, FreitagL, BaumbachJI. Ionmobility spectrome-
try in the diagnosis of sarcoidosis: results of a feasibility study. J Physiol
Pharmacol2007;58Suppl5:739–51.
28. Vazquez ES. Personalized therapy: an interdisciplinary challenge. Pers
Med2004;1:127–30.
29. Tzvetkov MV, Saadatmand AR, Lötsch J, Tegeder I, Stingl JC,
Brockmöller J. Genetically polymorphicOCT1: another piece in the pu-
zzle of the variable pharmacokinetics and pharmacodynamics of the
opioidergicdrugtramadol.ClinPharmacolTher2011;90:143–50.
30. BožinaN. Uloga farmakogenetičkihvarijacijau terapiji depresije. (diser-
tacija).Zagreb,Hrvatska:SveučilišteuZagrebu;2005.,str.116.
31. Sistonen J, Madadi P, Ross CJ i sur. Prediction of codeine toxicity in in-
fants and theirmothers using a novel combination ofmaternal genetic
markers.ClinPharmacolTher2012;91:692–9.
32. Piccoli P, Carrieri M, Salamon F, Bartolucci GB, MannoM. Fenotipizza-
zione in vivo del CYP 2E1 una nuova metodica per il monitoraggio bi-
ologico nell’esposizione occupazionale e sperimentale a benzene. Drug
SafetyUpdate2010;3:46–7.
33. Nagar S, Remmel RP. Uridine diphosphoglucuronosyltransferase phar-
macogeneticsandcancer.Oncogene2006;25:1659–72.
34. Marinković N, Pašalić D, Gršković B, Ferenčak G, Honović L, Stavljenić
RukavinaA.GenotypefrequenciesofUDP-glucuronosyltransferase1A1
promoter gene polymorphism in the population of healthy Croatian
pre-scholars.CollAntropol2008;32:725–9.
35. Li J, Menard V, Benish RL, Jurevic RJ i sur. Worldwide variation in hu-
man drug-metabolism enzyme genes CYP2B6 and UGT2B7: implicati-
onsforHIV/AIDStreatment.SummPharmacogenomics2012;13:555–70.
36. DragovicS,BoermaJS,vanBergenL,VermeulenNP,CommandeurJN.
Role of humanglutathione S-transferases in the inactivationof reactive
metabolitesofclozapine.ChemResToxicol2010;23:1467–76.
37. Kumar BS, Chung BC, Kwon OS, Jung BH. Discovery of common uri-
nary biomarkers for hepatotoxicity induced by carbon tetrachloride,
Od genomike dometabolomike analgetika u djece
